Posters include real-world dosing of Tyvaso DPI® in pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease, and data from the BREEZE open-label extension study of Tyvaso DPI detailing its long-term outcomes and dosing in patients with pulmonary arterial hypertension
United Therapeutics is sponsoring the Women in PH Luncheon and the Career Catalyst Luncheon: Speed Mentoring for Early Career PH Professionals
SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)-- United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced that five posters across its commercial and development portfolio in pulmonary hypertension (PH) will be presented at the Pulmonary Vascular Research Institute (PVRI) 2025 Annual Congress taking place January 29 through February 1, 2025 in Rio de Janeiro. In addition, professionals from United Therapeutics will participate in two speaking events associated with the congress.
United Therapeutics is also proud to sponsor the Women in PH Luncheon and the Career Catalyst Luncheon: Speed Mentoring for Early Career PH Professionals.
“At this year’s annual congress, we are delighted to share further findings that support long-term outcomes and dosing of Tyvaso DPI, as well as interim data from our PHINDER study that is beginning to reveal clues that could help to efficiently detect pulmonary hypertension associated with interstitial lung disease,” said Andrew Nelsen, PharmD, Vice President, Global Medical Affairs at United Therapeutics. “PVRI is a cornerstone event for the field of pulmonary vascular disease and provides an invaluable platform for collaboration and scientific exchange. We look forward to engaging with the scientific and medical communities about these latest developments.”
Posters include:
Burger, C., El-Kersh, K., Parikh, R., Wu, B., Thrasher, C., & Broderick, M. Real-World Dosing of Tyvaso DPI in Pulmonary Arterial Hypertension and Pulmonary Hypertension Associated with Interstitial Lung Disease.
Spikes, L., Bajwa, A., Burger, C., Ramani, G., Palevsky, H., Mehta, J., Joly, J., El-Kersh, K., Fisher, M., Eggert, M., Restrepo-Jaramillo, R., Sahay, S., Desai, S., Johri, S., Shah, T., Shapiro, S., Thrasher, C., Deng, C.Q., Smith, P., & Broderick, M. BREEZE Optional Extension Phase: Long-Term Outcomes with Tyvaso DPI in Patients with Pulmonary Arterial Hypertension.
Beck, E., Broderick, M., Chavarria, M.C., DerSarkissian, M., Kiely, D.G., Lee, D., Maher, K., Paxton, K., Sahay, S., Scholand, M.B., Shen. E., Shlobin, O., & Zisman, D. Interim Results from PHINDER: Pulmonary Hypertension Screening in Patients with Interstitial Lung Disease for Earlier Detection.
Argula, R., El-Kersh, K., Estrada, R., McLaughlin, V., Hong, T., Thrasher, C., & Broderick, M. Inhaled treprostinil for the treatment of pulmonary arterial hypertension in intermediate-high risk patients: a sub-group analysis of the TRIUMPH study.
Tomson, M.L., Gunzenhauser, D., Daczkowski, N., McGovern, A., Orozco, L., Clark, K., Mintz, A., O’Toole, B., Derma, A., Sista, P., & Rahaghi, F. Patient Reported Experience of Participants in the ARTISAN study for PAH.
Speaking events include:
Session 3: Real World Evidence/Real World Data, Wednesday, January 29, 10:40 to 11:15: 2nd Floor, Oceania IX. Co-chaired by Kellie Morland, PharmD, United Therapeutics.
Session 6: Challenges of Clinical Trial Design, Conduct & Endpoints, Wednesday, January 29, 12:22 to 12:30: 2nd Floor, Oceania IX – Insights on clinical trial design from the perspective of industry. Presented by C.Q. Deng, M.D., Ph.D., MPH, United Therapeutics.
Sponsored events include:
The Women in PH Luncheon, Friday, January 31, 11:15 to 13:00. Women in PH began as a way to support educational opportunities for women in PH and strengthen their professional network, aimed at building an inclusive, diverse community.
The Career Catalyst Luncheon: Speed Mentoring for Early Career PH Professionals, Thursday, January 30, 11:10 to 13:00. This event will offer micro-mentoring opportunities to early-career PH professionals and trainees, facilitating networking and connection-building between early-career PH professionals and providing opportunities to connect with renowned senior and mid-career PH researchers in a welcoming and informal setting.
About Tyvaso® Inhalation Solution and Tyvaso DPI® Inhalation Powder
INDICATION
TYVASO (treprostinil) Inhalation Solution and TYVASO DPI (treprostinil) Inhalation Powder are prostacyclin mimetics indicated for the treatment of:
Pulmonary arterial hypertension (PAH; WHO Group 1) to improve exercise ability. Studies with TYVASO establishing effectiveness predominately included patients with NYHA Functional Class III symptoms and etiologies of idiopathic or heritable PAH (56%) or PAH associated with connective tissue diseases (33%).
The effects diminish over the minimum recommended dosing interval of 4 hours; treatment timing can be adjusted for planned activities.
While there are long-term data on use of treprostinil by other routes of administration, nearly all clinical experience with inhaled treprostinil has been on a background of an endothelin receptor antagonist (ERA) and/or a phosphodiesterase type 5 (PDE-5) inhibitor. The controlled clinical experience with TYVASO was limited to 12 weeks in duration.
Pulmonary hypertension associated with interstitial lung disease (PH-ILD; WHO Group 3) to improve exercise ability. The study with TYVASO establishing effectiveness predominately included patients with etiologies of idiopathic interstitial pneumonia (IIP) (45%) inclusive of idiopathic pulmonary fibrosis (IPF), combined pulmonary fibrosis and emphysema (CPFE) (25%), and WHO Group 3 connective tissue disease (22%).
IMPORTANT SAFETY INFORMATION
WARNINGS AND PRECAUTIONS
TYVASO and TYVASO DPI are pulmonary and systemic vasodilators. In patients with low systemic arterial pressure, either product may produce symptomatic hypotension.
Both products inhibit platelet aggregation and increase the risk of bleeding.
Co-administration of a cytochrome P450 (CYP) 2C8 enzyme inhibitor (e.g., gemfibrozil) may increase exposure (both Cmax and AUC) to treprostinil. Co-administration of a CYP2C8 enzyme inducer (e.g., rifampin) may decrease exposure to treprostinil. Increased exposure is likely to increase adverse events associated with treprostinil administration, whereas decreased exposure is likely to reduce clinical effectiveness.
Like other inhaled prostaglandins, TYVASO and TYVASO DPI may cause acute bronchospasm. Patients with asthma or chronic obstructive pulmonary disease (COPD), or other bronchial hyperreactivity, are at increased risk for bronchospasm. Ensure that such patients are treated optimally for reactive airway disease prior to and during treatment with TYVASO and TYVASO DPI.
DRUG INTERACTIONS/SPECIFIC POPULATIONS
The concomitant use of either product with diuretics, antihypertensives, or other vasodilators may increase the risk of symptomatic hypotension.
Human pharmacokinetic studies with an oral formulation of treprostinil (treprostinil diolamine) indicated that co-administration of the cytochrome P450 (CYP) 2C8 enzyme inhibitor, gemfibrozil, increases exposure (both Cmax and AUC) to treprostinil. Co-administration of the CYP2C8 enzyme inducer, rifampin, decreases exposure to treprostinil. It is unclear if the safety and efficacy of treprostinil by the inhalation route are altered by inhibitors or inducers of CYP2C8.
Limited case reports of treprostinil use in pregnant women are insufficient to inform a drug-associated risk of adverse developmental outcomes. However, pulmonary arterial hypertension is associated with an increased risk of maternal and fetal mortality. There are no data on the presence of treprostinil in human milk, the effects on the breastfed infant, or the effects on milk production.
Safety and effectiveness in pediatric patients have not been established.
Across clinical studies used to establish the effectiveness of TYVASO in patients with PAH and PH ILD, 268 (47.8%) patients aged 65 years and over were enrolled. The treatment effects and safety profile observed in geriatric patients were similar to younger patients. In general, dose selection for an elderly patient should be cautious, reflecting the greater frequency of hepatic, renal, or cardiac dysfunction, and of concomitant diseases or other drug therapy.
ADVERSE REACTIONS
Pulmonary Arterial Hypertension (WHO Group 1)
In a 12-week, placebo-controlled study (TRIUMPH I) of 235 patients with PAH (WHO Group 1 and nearly all NYHA Functional Class III), the most common adverse reactions seen with TYVASO in ≥4% of PAH patients and more than 3% greater than placebo were cough (54% vs 29%), headache (41% vs 23%), throat irritation/pharyngolaryngeal pain (25% vs 14%), nausea (19% vs 11%), flushing (15% vs